High Risk Emergency Medicine



Similar documents
Guidelines and Protocols

Critical Bleeding Reversal Protocol

Pulmonary Embolism Treatment Update

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

Anticoagulation Therapy Update

LAMC Reversal Agent Guideline for Anticoagulants Time to resolution of hemostasis (hrs) Therapeutic Options

3/3/2015. Patrick Cobb, MD, FACP March 2015

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

Disclosures. Objective (NRHS) Self Assessment #2

New Anticoagulants: What to Use What to Avoid

The Brave New (Anticoagulant) World

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY

Anticoagulation and Reversal

Optimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015

Blood products and pharmaceutical emergencies

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

Antiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care

Disclosure. Outline. Objectives. I have no actual or potential conflict of interest in relation to this presentation.

Goals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center

New Anticoagulants and GI bleeding

9/5/14. Objectives. Atrial Fibrillation (AF)

Program Objectives. Why Use Anticoagulants? 6/5/2014

Building a Safe Anticoagulation Program By knowing that Safety is not about numbers, Safety is about an attitude..

Anticoagulation Essentials! Parenteral and Oral!

Managing Anticoagulation for Atrial Fibrillation 2015

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

Emerging therapies for Intracerebral Hemorrhage

CHADS score of 5 or 6 Recent (within 3mo) stroke or TIA Rheumatic valvular heart disease CHADs score of 3 or 4

48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.

EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013

Prostate Assessment Pathway Prostate Biopsy Alerts

The author has no disclosures

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness SOGH April

Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults

Time of Offset of Action The Trial

Making Sense of the Newer Anticoagulants

AR SAVES. INTRODUCTION AND UPDATES FOR ER PHYSICIANS. Nicolas Bianchi, MD. August 23 rd, 2012.

Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services

The New Oral Anticoagulants: When and When Not to Use Them Philip C. Comp, M.D., Ph.D. Professor of Medicine, University of Oklahoma Health Sciences

New Oral Anticoagulants

Traditional anticoagulants

Gruppo di lavoro: Malattie Tromboemboliche

5/21/2012. Perioperative Use Issues. On admission: During hospitalization:

The Role of the Newer Anticoagulants

Managing Anticoagulants, Antiplatelets, and NSAIDS in the Interventional Radiology Setting. Amy Huggins, BSN, RN

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

QUICK REFERENCE. Mary Cushman 1 Wendy Lim 2 Neil A Zakai 1. University of Vermont 2. McMaster University

RR 0.88 (95% CI: ) P=0.051 (superiority) 3.75

How To Treat Aneuricaagulation

DVT/PE Management with Rivaroxaban (Xarelto)

East Kent Prescribing Group

The speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.

Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia

Thrombosis and Hemostasis

Introduction. Background to this event. Raising awareness 09/11/2015

Appendix C Factors to consider when choosing between anticoagulant options and FAQs

Novel OACs: How should we use them?"

New oral anticoagulants and antiplatelets: Where do they fit? Meredith Hollinger, PharmD BCPS

Using CDS (Clinical Decision Support) for Quality Initiatives at a Community Hospital

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

STROKE PREVENTION IN ATRIAL FIBRILLATION

Anticoagulant reversal for intracranial hemorrhage (ICH) and other life threatening bleeding- update 2013 *

Anticoagulant Reversal

Duration of Dual Antiplatelet Therapy After Coronary Stenting

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.

How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne

Treatment with Apixaban

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285:

Objectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants

SCRN Medication Review. Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center

ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν

Financial Disclosures. Learning Objectives 05/06/2015. None

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Head Injury. Dr Sally McCarthy Medical Director ECI

DOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant

MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August Anticoagulants

Treatment with Rivaroxaban

NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS

Level III Stroke Center Data Collection Requirements

Reversal of Anticoagulants at UCDMC

Summary and general discussion

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

UW MEDICINE PATIENT EDUCATION. Xofigo Therapy. For metastatic prostate cancer. What is Xofigo? How does it work?

What we all Needs to Know about New and Old Anticoagulant and Antiplatelet Drugs. None related to this presentation 11/22/2012

Breakfast symposium: From hospital to home - the focus on the patient

New Oral Anticoagulants. How safe are they outside the trials?

A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS

Transcription:

High Risk Emergency Medicine Minor Head Injuries in Patients on Oral Anticoagulants David Thompson, MD, MPH Assistant Professor Department of Emergency Medicine

No relevant financial relationships to disclose Case: Head injury HPI: 67 yo m w/ PMH HTN, Gout, A fib, on coumadin & beta blocker, BIBA slipped and fell in the shower. Hit his head No LOC PE: 130/45, P 63, R 16, 99% RA, T 36.0 General: NAD HEENT: Abrasion and small hematoma to L temple, perrl, no dental trauma, Neck: in cervical collar Neuro: GCS 15, MAE x 4

INR 2.9 Negative imaging OK to discharge home?

Question: What is the risk of delayed intracranial hemorrhage in patients taking oral anticoagulants with minor head injury? He s on aspirin, not coumadin, does he need a second CTH?

Second CTH for Clopidogrel (Plavix)? Ticagrelor (Brilinta)? Prasugrel (Effient)? Second CTH for rivaroxiban (Xarelto)? Dabigatran (Pradaxa)?

Which patients with mild TBI should have a noncontrast head CT scan in the ED?

Pearl: Know your rules and what they re powered to detect.

ACEP Clinical Policy Ann Emerg Med. 2008 Dec;52(6):714 48.

Consider CTH if: Itshayek E, Rosenthal G, Neurosurgery. 2006 May;58(5):E851 6

Case series: 4 patients over 2 years Ages 65 86 Aspirin and enoxaparin Coumadin, on chronic dialysis, INR 3 Coumadin, INR 3 Coumadin, INR 3.2 All had CT#1 Normal All had delayed hemorrhage 3 required surgery 2 died

We recommend that elderly, anticoagulated mild TBI patients should be admitted for 24 to 48 hours of observation after injury. even a normal neurological exam and normal CT scan does not preclude subsequent rapid deterioration. J Trauma. 2006 Mar;60(3):553 7.

Retrospective review of prospectively collected head injury database and a trauma registry 77 patients taking warfarin w/ GCS 13 15 Avg age 68 Avg INR 4.4 64% had CTH performed 12.5% abnormal 28 Patients DC ed from the ED 10 (35%) had a normal CTH performed 18 returned to the ED, Dx ed w/ significant ICH 2 died at home of SDH found on autopsy Among these 20 patients, mortality 88%

45 patients admitted for observation 4 had abnormalities on CTH Within 8 18 hours, 80% of these patients had a decline in GCS to <10 Mortality 84% 12 patients presented to the ED in delayed fashion after their injury w/ neuro deficits. All had craniotomy Mortality 83%

Overall mortality in these 77 anticoagulated patients with minor head injury 80.6%. J Trauma. 2006 Jul;61(1):107 10.

Retrospective analysis of 1493 blunt head injury patients 159 on warfarin warfarin anticoagulation is an independent predictor of mortality after blunt TBI. Warfarin anticoagulation carries a six fold increase in TBI mortality.

Take Home Message Higher INR higher risk for ICH and death J Trauma. 2011 Jan;70(1):E1 5

3 year retrospective review of trauma registry Minor head injury (GCS 13 15) Taking Warfarin or Clopidogrel 141 patients met inclusion criteria 41 (29%) diagnosed with ICH 4 died Despite a presenting GCS score of 15, patients with minor head injury taking anticoagulation or antiplatelet therapy have a high incidence of intracranial hemorrhage.

J Trauma. 2011 Dec;71(6):1600 4. Retrospective review blunt trauma on warfarin or antiplatelet therapy 424 patients had a negative CTH#1 performed 362 patients had CTH2 performed

4 patients (1%) had abnormal CTH#2 None had declining neuro exams 3 discharged home 1 died of CV etiology Question: What is the optimal management of traumatic intracranial hemorrhage in patients taking warfarin?

Rapid warfarin reversal in Trauma. 2005 Nov;59(5):1131 7; discussion 1137 9.

Results Small study Enrolled 82 patients on Coumadin with head trauma 19 had intracranial bleeding 10% (2) died Compare to pre protocol mortality 48% Conclusion Rapid confirmation of ICH with CT scan and reversal of coagulopathy decreases progression of ICH and reduces mortality.

Do you have a plan to handle these intracranial bleeds? FFP (4 6 units) Warfarin Reversal Vitamin K (PO vs. IV) Prothrombin Complex Concentrate (PCC) Bebulin Factors 2, 7, 9, 10 Kcentra Factors 2, 7, 9, 10, Proteins C & S

LMWH & Heparin Administer protamine Dabigatran & Rivaroxaban Prothrombin Complex Concentrate (evidence for Rivaroxaban) Dialysis Charcoal Time

Antiplatelet agents On ASA/Plavix + ICH give platelets Baby Aspirin?

Level 1 trauma center 100 consecutive trauma patients > 65 on low dose ASA 4 cases of delayed hemorrhage on CT #2 1 fatal outcome, 1 required neurosurgery Recommended 12 24 hour routine repeat CTH vs. 48 hr. observation admission J Trauma. 2009 Sep;67(3):521 5 2 trauma centers, 4 community hospitals 1064 patients enrolled, 1000 CT ed Delayed hemorrhage in 4/687 warfarin patients, 2 died Zero cases of delayed hemorrhage in 243 clopidigrel patients Ann Emerg Med. 2012 Jun;59(6):460 8.

Patients on clopidigrel more likely to have immediate hemorrhage (12%) than those on warfarin (5%) Delayed hemorrhages on warfarin identified on days 1, 3, 3, and 7. Ann Emerg Med. 2012 Jun;59(6):457 9

Take Home Messages: No delayed hemorrhage in patients on clopidogrel. Observation & repeat imaging may not be worth the benefit for patients on warfarin. Recommend good discharge instructions for patients and next day phone call follow up. Dabigatran

J Neurosurg. 2013 May 1. Review of closed head injuries over 4 months Dabigatran (5) Warfarin (15) No anticoagulant (25) 2/5 (40%) of Dabigatran patients died. None of the other 35 patients died.

J Neurosurg. 2012 May;116(5):1093 6.

Pray-daxa? Bleed-ix?

My interpretation of the literature Risk goes up with INR and age. Repeat CTH unnecessary for antiplatelet agents. Observation & repeat imaging probably not worth the benefit for most patients on warfarin. Talk to your patients. Document appropriately. Good discharge instructions. Thank You!